

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
William Blake Winchell		01/31/2013	INDIVIDUAL:

RECEIVING PARTY DATA

Name:	Asterand, Inc.
Street Address:	440 Burroughs
Internal Address:	TechOne Suite 501
City:	Detroit
State/Country:	MICHIGAN
Postal Code:	48202
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 9

Property Type	Number	Word Mark
Registration Number:	2593077	ASTERAND
Registration Number:	2720343	
Registration Number:	2770234	TARGETEVALUATOR
Registration Number:	2825429	PHARMAGENE
Registration Number:	2833467	PHASE ZERO
Registration Number:	3018375	INDICATION SWITCH
Registration Number:	3034992	ASTERAND PARTNERS IN HUMAN TISSUE RESEARCH
Registration Number:	3700416	QUAD SET
Serial Number:	85134759	PROCURE

CORRESPONDENCE DATA

Fax Number: 2482030763
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.
 Phone: 248 203 0822

Email: ipmail@dykema.com
Correspondent Name: William F. Kolakowski III
Address Line 1: 39577 Woodward Avenue
Address Line 2: Suite 300
Address Line 4: Bloomfield Hills, MICHIGAN 48304

ATTORNEY DOCKET NUMBER:	083854-0013
NAME OF SUBMITTER:	William F. Kolakowski III
Signature:	/William F. Kolakowski III/
Date:	01/31/2013

Total Attachments: 4
source=Release#page1.tif
source=Release#page2.tif
source=Release#page3.tif
source=Release#page4.tif

RELEASE OF SECURITY INTEREST

This release of security interest is executed by Wm. Blake Winchell ("Collateral Agent") in its capacity as collateral agent for itself and for the benefit of the Represented Parties in the Second Lien Security Agreement dated July 22, 2011 (as amended, restated, supplemented or otherwise modified from time to time) between Asterand plc, Asterand, Inc. ("Grantor"), BioSeek LLC, Asterand UK Limited, Collateral Agent and the Represented Parties. All capitalized terms not otherwise defined herein shall have the respective meanings given in the Second Lien Security Agreement.

WHEREAS, pursuant to the Second Lien Security Agreement, the Grantor granted to the Collateral Agent a security interest ("Grant") in (i) certain of the Grantor's patents and patent applications ("Patents"), including the patents and patent applications set forth on Schedule A (ii) certain of the Grantor's trademark registrations and applications for registration ("Trademarks"), including the trademark registrations and applications for registration set forth on Schedule B, and (iii) certain of the Grantor's copyrights, which Grant was recorded in the U.S. Patent and Trademark Office on July 25, 2011 against the Patents at Reel 026645, Frame 0524 and on July 28, 2011 against the Trademarks at Reel 004593, Frame 0375.

WHEREAS, Grantor and Collateral Agent now wish to provide a document suitable for recording in the United States Patent and Trademark Office for purposes of recording the release, relinquishment and discharge of the Collateral Agent's security interest in the Patents and Trademarks;

NOW, THEREFORE, in consideration of and in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, the Collateral Agent, for itself and for the Represented Parties, hereby, as of July 31, 2012, relinquishes, releases and discharges its security interest in the Patents and Trademarks conveyed to Collateral Agent pursuant to the Second Lien Security Agreement and Grant, and/or any other agreement, and Collateral Agent hereby reassigns to Grantor any and all such right, title and interest that it may have in (i) the Patents, the inventions described and claimed therein, all reissues, continuations, continuations-in part, and divisionals of the foregoing, all rights to sue at law or in equity for any infringement or other impairment of the Patents including any past infringement or other impairment, including the right to receive all proceeds and damages thereof, and any other right, title and interest Collateral Agent may still have in the Patents, (ii) the Trademarks, the goodwill associated with the Trademarks, all rights to sue at law or in equity for any infringement or other impairment of the Trademarks including any past infringement or other impairment, including the right to receive all proceeds and damages thereof, and any other right, title and interest Collateral Agent may still have in the Trademarks, and (iii) the Copyrights, all rights to sue at law or in equity for any infringement or other impairment of the Copyrights including any past infringement or other impairment, including the right to receive all proceeds and damages thereof, and any other right, title and interest Collateral Agent may still have in the Copyrights. Collateral Agent further agrees to execute and deliver to Grantor any and all further documents or instruments and do any and all further acts which Grantor (or Grantor's agents or designees) reasonably request, all at the sole expense of Grantor, in order to confirm Grantor's right, title and interest in and to the Patents, Trademarks, and Copyrights and that Collateral Agent makes

SCHEDULE A

<u>Patent No.</u>	<u>Issue Date</u>	<u>App. No.</u>	<u>Filing Date</u>	<u>Title/Notes</u>
6,444,477	09/03/2002	09/722,379	11/28/2000	Assay method for detecting 5-HT2B antagonists
7,429,607	09/30/2008	10/364,672	02/12/2003	5-HT.sub.2B receptor antagonists
		60/626,940	11/12/2004	EP2 Receptor Agonists
		11/019,133	12/22/2004	EP2 Receptor Agonists
7,326,732	02/05/2008	11/055,724	02/11/2005	EP2 receptor agonists
		10/564,010	01/11/2006	5-Ht2b Receptor Antagonists
		10/583,896	06/07/2006	EP2 Receptor Agonists
7,662,839	02/16/2010	11/950,613	12/05/2007	EP2 receptor agonists
8,080,567	12/20/2011	12/063,421	02/08/2008	EP2 Receptor Agonists
		12/865,321	07/09/2010	Biaryl Amides

SCHEDULE B

<u>Registration No.</u>	<u>Registration Date</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Mark</u>
2,593,077	07/09/2002	78/057,531	04/09/2001	ASTERAND
2,720,343	06/03/2003	76/050,803	05/17/2000	Miscellaneous Design
2,770,234	09/30/2003	78/038,435	12/08/2000	TARGETEVALUATOR
2,825,429	03/23/2004	75/889,341	01/06/2000	PHARMAGENE
2,833,467	04/20/2004	75/573,307	10/19/1998	PHASE ZERO
3,018,375	11/22/2005	78/061,142	04/30/2001	INDICATION SWITCH
3,034,992	12/27/2005	78/481,691	09/10/2004	ASTERAND PARTNERS IN HUMAN TISSUE RESEARCH & Design
3,700,416	10/20/2009	78/862,575	04/17/2006	QUAD SET
		85/134,759	09/21/2010	PROCURE